Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing.

Simple item page
dc.contributor.authorLodise, Thomas P
dc.contributor.authorBhavnani, Sujata M
dc.contributor.authorAmbrose, Paul G
dc.contributor.authorSader, Helio S
dc.contributor.authorAndes, David R
dc.contributor.authorPogue, Jason M
dc.contributor.orcidhttps://orcid.org/0000-0002-4730-0655
dc.date.accessioned2025-02-07T19:34:58Z
dc.date.available2025-02-07T19:34:58Z
dc.date.issued12/17/2024
dc.descriptionClick on the Resource Link to access the article (may not be free).
dc.description.abstractThe in vitro susceptibility testing interpretive criteria (STIC) for TZP against Enterobacterales were recently updated by the Food and Drug Administration (FDA), Clinical & Laboratory Standards Institute (CLSI), and European Committee on Antimicrobial Susceptibility Testing (EUCAST). The United States Committee on Antimicrobial Susceptibility Testing (USCAST) also recently reviewed TZP STIC for Enterobacterales and arrived at different STIC for Enterobacterales and herein we explain our recommendations and rationale behind them. Based on our review of the available data, USCAST does not recommend TZP STIC for certain Enterobacterales species that have a moderate to high likelihood of clinically significant AmpC production (E. cloacae, C. freundii, and K. aerogenes only) or for third-generation cephalosporin-non-susceptible (3GC-NS) Enterobacterales. USCAST recommends a TZP susceptibility breakpoint of ≤ 16/4 mg/L for third-generation cephalosporin-susceptible (3GC-S) Enterobacterales but only endorses the use of extended infusion TZP regimens for patients with infections due to these pathogens.
dc.description.urihttps://doi.org/10.1093/cid/ciae328
dc.identifier.citationLodise TP, Bhavnani SM, Ambrose PG, Sader HS, Andes D, Pogue JM. Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing. Clin Infect Dis. 2024 Dec 17;79(6):1354-1362. doi: 10.1093/cid/ciae328. PMID: 38902929; PMCID: PMC11650869.
dc.identifier.issn1058-4838
dc.identifier.other38902929
dc.identifier.urihttps://hdl.handle.net/20.500.14303/745
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofClinical Infectious Diseases
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectAmpC
dc.subjectESBL
dc.subjectEnterobacterales
dc.subjectpiperacillin/tazobactam
dc.subjectsusceptibility
dc.titlePiperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Lodise, Thomas P. Publications